Artivion (NYSE:AORT) SVP Andrew Green Sells 11,480 Shares

Artivion, Inc. (NYSE:AORT) SVP Andrew Green sold 11,480 shares of the business’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $24.97, for a total transaction of $286,655.60. Following the transaction, the senior vice president owned 40,160 shares in the company, valued at $1,002,795.20. This represents a 22.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Artivion Trading Up 1.9%

Shares of NYSE:AORT opened at $25.13 on Friday. Artivion, Inc. has a 52-week low of $19.16 and a 52-week high of $48.25. The company has a market capitalization of $1.23 billion, a P/E ratio of -358.92 and a beta of 1.25. The company has a 50-day simple moving average of $26.27 and a 200 day simple moving average of $28.78. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.51 and a current ratio of 3.47.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter. The business had revenue of $125.76 million during the quarter, compared to analysts’ expectations of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. Sell-side analysts forecast that Artivion, Inc. will post 0.45 earnings per share for the current year.

Hedge Funds Weigh In On Artivion

A number of large investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd acquired a new stake in Artivion during the 3rd quarter worth approximately $27,000. Rockefeller Capital Management L.P. grew its holdings in Artivion by 150.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock valued at $30,000 after buying an additional 399 shares in the last quarter. Larson Financial Group LLC increased its position in Artivion by 148.5% during the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after buying an additional 563 shares during the period. Smartleaf Asset Management LLC increased its position in Artivion by 47.7% during the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock worth $52,000 after buying an additional 538 shares during the period. Finally, Kemnay Advisory Services Inc. bought a new position in Artivion during the 4th quarter worth $79,000. Institutional investors own 86.37% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Weiss Ratings lowered Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Canaccord Genuity Group raised their price target on Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, August 18th. Stifel Nicolaus set a $45.00 price objective on shares of Artivion in a research report on Monday, June 1st. Citigroup reiterated a “market outperform” rating on shares of Artivion in a report on Tuesday, July 21st. Finally, Wall Street Zen lowered shares of Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Artivion presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.83.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.